HeyJaredSunir J. Garg
- Indexed articles, last 90 days
- 5
- Latest publication
- Aug 27, 2026
- Outlet visibility, for Healio
- Top 500K sites
- Earliest in this view
- Aug 12, 2026
Latest articles
Post hoc analysis can guide geographic atrophy treatment decisions, patient discussions (opens the original)
Read excerpt
In this video, Sunir J. Garg, MD, FACS, FASRS, talked about a post hoc analysis of pegcetacoplan clinical trials in geographic atrophy presented at the American Society of Retina Specialists annual meeting. Garg, chief of the retina service at Wills Eye Hospital and professor of ophthalmology at Thomas Jefferson University, said the results of this analysis of Syfovre (pegcetacoplan injection, Biogen) can help determine which patients would benefit the most from treatment as well as help explain
Registry analysis explores real-world use of aflibercept 8 mg in diabetic macular edema (opens the original)
Read excerpt
Results of a registry analysis on the real-world use of aflibercept 8 mg in treatment-naive and previously treated eyes with diabetic macular edema were presented at the American Society of Retina Specialists annual meeting. âThis is a registry study [on Eylea HD (aflibercept 8 mg, Regeneron)], so we donât have individual patient-level data, and unfortunately, at this time, we donât have the ability to look at the OCTs, but this, to me, is quite helpful in my day-to-day decision-makingâ
âIncredibleâ results seen with intravitreal phase 2 gene therapy for wet AMD (opens the original)
Read excerpt
In this video interview, Sunir J. Garg, MD, FACS, FASRS, discussed 2-year results of the phase 2 LUNA study on ixoberogene soroparvovec, an intravitreal gene therapy from Adverum Biotechnologies for wet age-related macular degeneration. The results were presented at the American Society of Retina Specialists annual meeting. âEverybody received one injection, and it reduced the need for supplemental treatment by 90% over 2 years while maintaining stable visual acuity as well as stable, and real
VEGF/Ang-2 inhibitor âpotentially exciting developmentâ in diabetic macular edema (opens the original)
Read excerpt
Sunir J. Garg, MD, FACS, FASRS, discussed findings from a proof-of-concept clinical trial comparing OLN324, a bispecific antibody targeting VEGF and Ang-2, with faricimab in patients with diabetic macular edema in this video with Healio. The results were presented at the American Society of Retina Specialists annual meeting. OLN324 (Ollin Biosciences) demonstrated rapid drying of the macula that was âat least comparable, if not better,â than that seen with Vabysmo (faricimab, Genentech), acc
Novel dual-targeting biologic shows potential in treatment-naive wet AMD (opens the original)
Read excerpt
Sunir J. Garg, MD, FACS, FASRS, spoke about TH103, a novel biologic targeting both VEGF and heparan sulfate proteoglycans, in treatment-naive patients with wet age-related macular degeneration in this video interview. Results from the phase 1 single ascending dose study of TH103 (Kalaris Therapeutics) were presented at the American Society of Retina Specialists annual meeting. âThereâs a lot of potential here, but obviously more work needs to be done,â Garg, chief of the retina service of
Publishing over time
Last 90 days. Choose a month to open its work.
Recurring subjects
Named in the text we hold. One piece can cover several.
Audience
Top 500K sites
For Healio, the outlet · Measured Aug 1, 2026
Website popularity band, not a count of readers or article views.
About this data
Counts cover the work we have indexed. Tone needs enough text and a confident classification. Excerpts and episode notes are not full articles or transcripts.
Identity or attribution wrong? Suggest a correction.